With the aim of examining central opioid influences on the control of luteinizing hormone (LH) secretion, we evaluated the LH response to naloxone, an opioid receptor antagonist, in patients affected by normo-, hyper-, and hypogonadotropic amenorrhea, polycystic ovarian disease and hyperprolactinemia. The results indicate that opioid influences are altered in well-defined pathologic conditions (hyperprolactinemia, obesity), in addition to being modified by gonadal steroids.
Impairment of opioid control of luteinizing hormone secretion in menstrual disorders / F., Petraglia; G., D'Ambrogio; G., Comitini; FACCHINETTI, Fabio; VOLPE, Annibale; A. R., Genazzani. - In: FERTILITY AND STERILITY. - ISSN 0015-0282. - STAMPA. - 43:(1985), pp. 534-540.
Impairment of opioid control of luteinizing hormone secretion in menstrual disorders.
FACCHINETTI, Fabio;VOLPE, Annibale;
1985
Abstract
With the aim of examining central opioid influences on the control of luteinizing hormone (LH) secretion, we evaluated the LH response to naloxone, an opioid receptor antagonist, in patients affected by normo-, hyper-, and hypogonadotropic amenorrhea, polycystic ovarian disease and hyperprolactinemia. The results indicate that opioid influences are altered in well-defined pathologic conditions (hyperprolactinemia, obesity), in addition to being modified by gonadal steroids.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
